<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363644">
  <stage>Registered</stage>
  <submitdate>7/03/2013</submitdate>
  <approvaldate>10/04/2013</approvaldate>
  <actrnumber>ACTRN12613000384752</actrnumber>
  <trial_identification>
    <studytitle>Comparison between different doses of gonadotropin-releasing hormone agonist used in short stimulation protocol in infertile women undergoing IVF</studytitle>
    <scientifictitle>Hormonal responses and clinical outcome following three doses of gonadotropin-releasing hormone agonist used in short stimulation protocol in infertile patients undergoing in vitro fertilization cycles</scientifictitle>
    <utrn> U1111-1139-2471</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Infertility</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fertility including in vitro fertilisation</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Ovulatory patients undergoing in vitro fertilization cycles will start treatment with intramuscular injection of  urinary gonadotropins, 2 ampoules (150 IU) per day and subcutaneous injections of GnRH-a (Triptorelin) on the first day of the menstrual period and continued till the day of human chorionic gonadotropins (hCG) administration. We administered human chorionic gonadotropin (hCG) when at least three follicles of 16 mm or more in diameter and adequate estradiol plasma concentrations were detected. Patients will be randomly assigned to three groups; group A, group B and group C . The daily dose of Triptorelin will be 0.1 mg, 50 ug, and 25 ug in groups A, B and C respectively.' </interventions>
    <comparator>Patients will be  randomly assigned to three groups; group A, group B and group C .  The daily dose of Triptorelin will be  0.1 mg, 50 ug, and 25 ug in groups A, B and C respectively. Group A in which the patients will recieve the routine dose of 0.1 Triptorelin will be the control group. </comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pregnancy rate defined as the detection of rising B human chorionic gonadotropin titre in the serum and  the ultrasound diagnosis of intruterine gestational sac. </outcome>
      <timepoint>within four weeks of intervention commencement</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Occurence of LH surge by the measurement of LH level in the serum</outcome>
      <timepoint>Within two weeks of intervention commencement</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Infertile patients undergoing in vitrofertilization cycles, </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>42</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients with ovarian failure</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>The demographic data of the patients, hormonal levels, stimulation requirements and outcome variables will be compared for the three groups. Results will be presented as mean +/- standard deviation.  Where appropriate, x2 test and t-test will be used for analysis using SPSS for Windows version 11.0 (SPSS Inc., Chicago, IL USA). P&lt;.05 was considered statistically significant.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/01/2012</anticipatedstartdate>
    <actualstartdate>1/01/2012</actualstartdate>
    <anticipatedenddate>1/06/2013</anticipatedenddate>
    <actualenddate />
    <samplesize>90</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Sarhan IVF Cntre</primarysponsorname>
    <primarysponsoraddress>No 10 Alkawmya Street, 
11144, Zagazig, Egypt</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary> Gonadotropin releasing hormone agonist (GnRH-a) is used routinely in controlled ovarian stimulation for assisted reproduction either in its short (flare-up) or long protocol. The routine daily dose of the different agonists was introduced by trials and is not uniformly established.
The objective of this prospective randomized controlled study was to characterize the daily changes in the levels of luteinizing hormone (LH) and estradiol (E2) and to compare the intracytoplasmic sperm injection (ICSI) outcome with 3 different doses of the GnRH-a used in a short protocol for normal ovulatory females.
Patientswill be  randomly assigned to three groups; group A (N=34), group B (N=34) and group C (N=23). All the patients will start treatment with urinary gonadotropins, 2 ampoules per day and GnRH-a (Triptorelin) on the first day of the menstrual period and continued till the day of human chorionic gonadotropins (hCG) administration. The daily dose of Triptorelin will be 0.1 mg, 50 ug, and 25 ug in groups A, B and C respectively.
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Zagazig University Fuculty of Medicine Ethical committee  ZU-IRB</ethicname>
      <ethicaddress>Zagazig Univeersity Faculty of Medicine

11118, Zagazig, Egypt</ethicaddress>
      <ethicapprovaldate>15/07/2011</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>10/05/2011</ethicsubmitdate>
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Abdulmagid Sarhan</name>
      <address>Professor/ Abdulmagid Sarhan, Professor Zagazig University
Borg Salma, Talaat Harb Street, 
11014, Zagazig, Egypt</address>
      <phone>+201227972674</phone>
      <fax />
      <email>sarhan_a@hotmail.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Abdulmagid Sarhan</name>
      <address>Professor/ Abdulmagid Sarhan, Professor Zagazig University
Borg Salma Talaat Harb Streat, 
11014, Zagazig, Egypt</address>
      <phone>+201227972674</phone>
      <fax />
      <email>sarhan_a@hotmail.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Professor/ Abdulmagid Sarhan</name>
      <address>Professor/ Abdulmagid Sarhan, Professor Zagazig University
Borg Salma Talaat Harb Street, 
11014, Zagazig, Egypt</address>
      <phone>+201227972674</phone>
      <fax />
      <email>sarhan_a@hotmail.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Abdulmagid Sarhan</name>
      <address>Borg Salma Talaat Harb Streat, 
11014, Zagazig, Egypt</address>
      <phone>+201227972674</phone>
      <fax />
      <email>sarhan_a@hotmail.com</email>
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>